Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)

Next Previous
Trial Profile

Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary) ; Raltegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OPTIPRIM

Most Recent Events

  • 22 Jan 2018 Results of estimation of residual drug concentrations (Ctrough) and exposures (AUC) by using published pharmacokinetic models published in the Journal of Antimicrobial Chemotherapy
  • 26 Jul 2017 Results of pharmacokinetic substudy presented at the 9th International AIDS Society Conference on HIV Science
  • 04 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top